Below The Knee | Market Signal

PFS Held the Line on $127.14. Three Insurers Are Suing CMS Over a Different Number Entirely.

CMS released the CY2027 Physician Fee Schedule proposed rule on July 14 — exactly on the calendar cadence flagged in this newsletter two editions running, and exactly as predicted on the headline number. Sheet-form skin substitutes stay classified as incident-to supplies in the non-facility setting, paid at $127.14 per square centimeter. Same rate OPPS held two weeks ago. Same justification pattern CMS has now run twice: hold the number, wait for more claims data, revisit later. But "no change" undersells what's actually in this rule. Two things are genuinely new. First, CMS proposes establishing a national payment methodology for non-sheet form skin substitutes — gels, powders, injectables, 3D-printed constructs — for the first time. Right now those products are left to individual MAC discretion, meaning payment varies by region; this rule would replace that patchwork with a single national approach, something manufacturer groups have been requesting since the CY2026 rule left the category unaddressed. Second, CMS proposes clarifying that certain skin substitutes would not be excluded from the definition of a "Part B rebatable drug" under the Medicare Drug Inflation Rebate Program — meaning some skin substitute manufacturers could owe CMS a rebate if their prices rise faster than CPI-U, a financial exposure that's never applied to this category before. Comments close September 14.

There's also a genuine bright spot buried in the same rule, and it's easy to miss next to the CAMPs headlines: CMS proposes converting Real-Time Fluorescence Wound Imaging from a Category III CPT code (0598T/0599T) to a permanent Category I code (placeholder 976XX). This is the exact structural unlock this newsletter's Innovation Index has flagged as an "Opportunity" for the diagnostics category — Category I status means standard national coverage and valuation, not payer discretion. MolecuLight is the best-positioned name in this category on published evidence alone. This rule isn't just a story about what CMS won't fix.

Buried further in: CMS proposes making 340B Part D claims data reporting mandatory for 340B hospitals starting in 2027. Right now it's voluntary. Pair that with the OPPS rule's 340B payment cut covered two editions ago — ASP plus 6% down to ASP minus 33.4% for 340B-acquired drugs — and the pattern holds across both rulemaking tracks this cycle: CMS is decisive and specific when it comes to 340B, and deliberately vague and delayed when it comes to the core CAMPs rate. Two rules, same posture, six weeks apart.

Meanwhile a completely different CMS fight escalated in federal court. Elevance Health — the same company that paid CMS $342 million in a Medicare Advantage billing settlement covered here two editions ago — filed suit against CMS on July 1 over an unrelated matter: it says CMS owes it $115 million in 2027 quality bonus payments after refusing to apply the same star-ratings recalculation methodology it used for Clover Health following a May federal court ruling. SCAN Health Plan filed a near-identical suit July 7, claiming $125 million. Alignment Healthcare filed July 10, claiming $50 million. Same court, same legal theory, roughly $290 million in combined claimed underpayment across three insurers.

Same month, same company: CMS collected $342 million from Elevance over one dispute and stands accused of shorting it $115 million in another. That's not really a contradiction — it's a preview of where the live fights in this market actually sit right now. Less about wound care rulemaking specifically, more about the machinery of what CMS says it owes versus what it says is owed to it, across every program touching this space.

Add HHS OIG's public signal this week that it's intensifying fraud enforcement, plus a $550,000 False Claims Act settlement against an unnamed device company over billing and kickback allegations, and the enforcement drumbeat that started with Elevance two editions ago hasn't slowed down. Skin substitute and CAMP manufacturers should treat this as sustained weather, not a passing front.

Here's the week.

REIMBURSEMENT & POLICY

Reimbursement | CMS Issues CY2027 Physician Fee Schedule Proposed Rule — Flat Rate Holds, But Two New Skin Substitute Proposals Buried Inside

CMS released the CY2027 Physician Fee Schedule proposed rule July 14. Sheet-form skin substitutes remain classified as incident-to supplies paid at $127.14/cm² in the non-facility setting — no change from CY2026, mirroring the OPPS decision two weeks prior. But two other skin-substitute-specific proposals are new this cycle and easy to miss in the topline coverage. First: CMS proposes a national payment methodology for non-sheet form skin substitutes — gels, powders, injectables, 3D-printed constructs — replacing the current system where individual MACs set payment regionally. Second: CMS proposes clarifying that certain skin substitutes would not be excluded from the definition of a "Part B rebatable drug" under the Medicare Drug Inflation Rebate Program, which could expose manufacturers to CPI-U-linked rebate liability for the first time if their prices outpace inflation. Elsewhere in the rule: the standard conversion factor decreases 1.19% for QP/APM participants and 1.68% for everyone else, driven by the expiration of the one-time 2.50% statutory increase that applied only in CY2026, partially offset by a 0.53% adjustment tied to proposed work RVU changes. CMS also proposes reducing reliance on specialty-specific practice-expense per-hour data, changes to indirect practice-expense calculations for SNF stays, reduced payment when a same-day, same-physician E/M visit is billed alongside a global procedure, and making 340B Part D claims data reporting mandatory for 340B hospitals starting in 2027, up from voluntary today. Comments close September 14; final rule expected in the fall.

The BTK read: The headline number confirms what this newsletter flagged two editions running — PFS mirrors OPPS on the sheet-form flat rate, and the office-based site of care gets no different treatment than hospital outpatient. That removes the last open question about where CMS might move independently on the core CAMPs rate before CY2028. It won't. But treating this rule as "no change" misses real movement at the edges: a national non-sheet-form payment methodology is a genuine structural shift for a product category that's had zero payment consistency, and the inflation rebate exposure is a new cost line for any manufacturer whose pricing strategy assumed skin substitutes sat outside that program. Neither of these has a dollar figure attached yet — worth tracking closely as comment-period detail firms up. The mandatory 340B reporting change is worth its own attention: CMS is building the data infrastructure to enforce its 340B cuts with more precision, at the same time it says it doesn't have enough data to differentiate CAMPs rates. That's not a resourcing gap — it's a sequencing choice about which data pipeline gets built first.

Regulatory | CMS Proposes Category I CPT Code for Real-Time Fluorescence Wound Imaging

The same PFS rule proposes converting Real-Time Fluorescence Wound Imaging from Category III CPT codes (0598T/0599T) to a permanent Category I code, placeholder 976XX. Category III codes are temporary and don't carry a nationally established Medicare valuation — coverage and payment are effectively left to payer discretion. Category I status changes that: it puts the code through standard RVU valuation and national coverage treatment.

The BTK read: This is the one genuinely positive skin-and-wound-adjacent story in a rule mostly defined by what didn't move. It's also not a surprise to anyone tracking this closely — the Innovation Index has carried fluorescence imaging CPT conversion as a flagged "Opportunity" for the diagnostics category, with MolecuLight named as best-positioned on the strength of 100+ published studies, well before this rule dropped. Category I conversion is the unlock that turns a technology from "reimbursed if your MAC feels like it" into "reimbursed as a matter of national policy." Worth watching the actual proposed valuation once CMS publishes the full addenda — a Category I code with a weak RVU is a smaller win than a Category I code with a real one. But the structural direction here is unambiguous, and it's the kind of forward signal this platform exists to catch before it shows up as a press release.

Reimbursement | Elevance, SCAN, and Alignment Sue CMS Over Medicare Advantage Star Ratings

Elevance Health filed suit against CMS and HHS on July 1, alleging CMS unlawfully refused to recalculate Elevance's 2026 Medicare Advantage star ratings using the same methodology applied to Clover Health after a May 27 federal court ruling found CMS improperly used measures not adopted by regulation. Elevance claims the refusal will cost it $115 million in 2027 quality bonus payments across five MA contracts. SCAN Health Plan filed a nearly identical suit July 7 seeking to raise its rating from 4 to 4.5 stars, claiming $125 million in lost value. Alignment Healthcare filed July 10 claiming $50 million. All three suits rest on the same theory: CMS gave Clover Health the benefit of the full court ruling but is withholding the same treatment from other insurers affected by the same measures.

The BTK read: Same month, same insurer, opposite CMS relationship — Elevance paid CMS $342 million in a billing settlement two editions ago and is now suing CMS for $115 million it says it's owed. That whiplash is the real story here, not the star-ratings mechanics specifically. MA star ratings directly set plan reimbursement generosity and quality bonus payments, which flow downstream into how aggressively MA plans cover advanced wound care, vascular intervention, and limb salvage therapies. Three insurers fighting CMS over roughly $290 million combined is a signal that MA plan economics are tightening across the board — worth watching for coverage-policy tightening on discretionary or high-cost advanced therapies as an indirect consequence.

Regulatory | HHS OIG Signals Intensified Healthcare Fraud Crackdown

HHS OIG signaled an intensified enforcement effort targeting healthcare fraud this week; full details of the announcement weren't accessible at publication.

The BTK read: Directionally consistent with everything else this month — the Elevance settlement, the new lawsuits, and now a public OIG signal. Historically, heightened OIG scrutiny lands hardest on high-cost billing categories with a documented fraud history, and skin substitutes/CAMP fit that description. Compliance posture, not clinical differentiation, is the thing to have buttoned up if OIG's next target list includes this category.

Also this week, briefly: A medical device company agreed to pay over $550,000 to resolve False Claims Act allegations tied to improper billing or kickback schemes involving federal healthcare programs (company not named in the DOJ release). Another data point in the same enforcement pattern — worth watching for whether it names names in follow-up coverage.

VASCULAR INTERVENTION

Market | AngioDynamics Posts Record FY2026 Results — Seventh Straight Quarter of Double-Digit Med Tech Growth

AngioDynamics reported fiscal year 2026 results July 14: Med Tech segment net sales of $150.0 million, up 18.4%, marking a seventh consecutive quarter of double-digit Med Tech growth. The company achieved full-year profitability with adjusted EBITDA of $13.2 million. Auryon atherectomy, thrombus management, and NanoKnife platforms drove the growth. The company also disclosed FDA IDE approval for the PAVE study (AngioVac, right-sided infective endocarditis) and FDA 510(k) clearance for AlphaVac, both strengthening its thrombectomy and vascular intervention portfolio.

The BTK read: This is the earnings print flagged as a key date in two prior editions, and it delivered. Seven straight quarters of double-digit Med Tech growth is a real trend line, not a comp effect, and Auryon's continued momentum matters directly for the peripheral atherectomy competitive landscape this newsletter tracks closely. The AlphaVac clearance and PAVE IDE approval extend the thrombectomy story beyond Auryon alone — AngioDynamics is building a multi-platform vascular portfolio, not a single-product story. Worth revisiting next quarter for whether the growth rate holds against tougher comps.

Regulatory | J&J Wins FDA Approval for Dual-Energy Ablation Catheter

Johnson & Johnson MedTech received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, enabling electrophysiologists to deliver both radiofrequency and pulsed field energy through a single catheter for atrial fibrillation treatment.

The BTK read: Cardiac EP, not BTK core coverage — but the competitive dynamics are instructive. J&J is now positioned to compete directly with Medtronic and Boston Scientific in pulsed field ablation using a dual-energy approach, and the same large strategics investing heavily in energy-based catheter innovation for cardiac indications tend to bring that R&D infrastructure to peripheral vascular platforms eventually. Worth a watch for cross-pollination into BTK-relevant peripheral ablation and thrombectomy technology over the next 12–24 months.

Market | Humacyte Adds Nephrologist Advisors Ahead of Dialysis Access ATEV Commercialization

Humacyte appointed nephrologists Robert J. Kossmann and Prabir Roy-Chaudhury as advisors to build health-economic, reimbursement, and market-access strategy for its acellular tissue engineered vessel (ATEV) in hemodialysis access. The appointments follow positive Phase 3 V012 dialysis access study results in women, and precede Humacyte's planned supplemental BLA filing with the FDA.

The BTK read: This is commercialization infrastructure-building, and the timing — advisors added right before a planned supplemental BLA — signals Humacyte believes the clinical case is closed and the reimbursement case is the next hurdle. Dialysis access is a high-volume, high-frequency-procedure population directly adjacent to BTK's vascular intervention and limb salvage coverage; ATEV's bioengineered vessel approach is a genuinely different mechanism than synthetic grafts or fistulas. Worth tracking the supplemental BLA timeline closely — reimbursement strategy work this far ahead of filing suggests Humacyte expects approval, not just hopes for it.

Also this week, briefly: Zacks Research downgraded LeMaitre Vascular (NASDAQ: LMAT) from strong-buy to hold on July 8, citing valuation rather than operational concerns. Johnson & Johnson also reported Q2 2026 earnings July 15 — revenue of $25.31 billion, EPS of $2.90, both ahead of consensus — and raised FY2026 EPS guidance to $11.60–$11.75, a broadly positive read for large-cap MedTech demand heading into H2.

WOUND CARE

Market | Sanuwave Beats Revised Q2 2026 Revenue Guidance

Sanuwave Health reported preliminary Q2 2026 revenue of $9.6–$9.8 million, above the high end of its revised guidance range of $8.5–$9.5 million.

The BTK read: Worth the callback — this is the same Sanuwave that cut guidance and was dropped from the Russell 2000 Dynamic Index a few editions ago, with management directly attributing the pressure to wound clinic closures tied to the CAMPs reimbursement reset. A beat against reduced guidance isn't a full recovery, but it's the first positive data point in that arc. Whether it's stabilization or a low bar worth clearing is a Q3 print question, not a Q2 one.

Also this week — briefs:

SKIN SUBSTITUTES / CAMP

Regulatory | BioStem Technologies Files Form 10 for Nasdaq Uplisting

BioStem Technologies filed a Form 10 registration statement with the SEC, initiating the process of becoming a fully reporting public company and a step toward a potential Nasdaq uplisting.

The BTK read: A capital-markets-access move, not a clinical or commercial one — but it matters for a perinatal tissue-based CAMP manufacturer navigating the same $127.14 flat-rate environment as every other skin substitute company right now. Improved capital markets access ahead of a potential CY2028 rate differentiation is a reasonable hedge if BioStem believes its regulatory classification will benefit from that eventual split.

Also this week, briefly: Auxilium Health closed an oversubscribed $3.4 million seed round for its Aer biomaterial platform, an early but notable signal of continued investor interest in novel biomaterial approaches. Allergan Aesthetics (AbbVie) announced SkinMedica is expanding its regenerative science investment with a new advisory board and R&D facility expansion — primarily an aesthetics story, but one more data point on aesthetic/wound-healing biologics crossover investment.

📡 BTK Intelligence Dashboard

Woundcare, Limb Salvage, Foot and Ankle and Vascular - all scored, indexed and monitored. Real-time capital signals. Curated news and alerts. AI-powered queries. The way no market intelligence platform has done before.

intelligence.belowtheknee.co/sign-up →

FINANCE | CAPITAL ACTIVITY

Investment | Frazier Healthcare Partners to Acquire MatrixCare in $490M Deal

Frazier Healthcare Partners announced plans to acquire MatrixCare, a post-acute and long-term care software provider used for EHR and care management in skilled nursing, home health, and hospice settings.

The BTK read: Tangential to core BTK coverage, but not irrelevant — MatrixCare's documentation and outcomes-tracking infrastructure underpins how wound care gets billed and reported in SNF and home health settings, exactly the site-of-care categories under the most reimbursement pressure right now. A $490 million check into post-acute care infrastructure is a bet that documentation quality becomes more, not less, important as CMS tightens billing scrutiny across this market.

Also this week, briefly: CONMED Corporation named John E. Gallagher as Chief Financial Officer, effective July 15, bringing nearly three decades of healthcare finance experience from Certara, Cue Health, and Becton Dickinson.

📅 UPCOMING EVENTS

August 6–9 | Nashville, TN — APMA Annual Scientific Meeting — Gaylord Opryland

September 10–11 | New Orleans, LA — IPAWS & Tissue Repair Summit (Kernexus) — The Ritz-Carlton (BTK Official Market Intelligence Partner)

September 14–16 | Louisville, KY — NAWCO HEAL Conference 2026

September 23–27 | Kuala Lumpur, Malaysia — WUWHS 2026

October 15–18 | Las Vegas, NV — SAWC Fall 2026 — Caesars Palace

October 22–24 | Anaheim, CA — DFCon 2026 — JW Marriott

November 6 | Virtual — WoundCon Fall 2026

December 9–12 | Phoenix, AZ — Desert Foot — Multi-Disciplinary Limb Salvage & Wound Care Conference

Not subscribed? → newsletter.belowtheknee.co · Forward this to one person in your network who works in this space.

See you next week — Scott